Loading...
•
Sep 30, 2022
Sangamo Q3 2022 Earnings Report
Reported business highlights and financial results for the third quarter of 2022.
Key Takeaways
Sangamo Therapeutics reported a net loss of $53.2 million, or $0.34 per share, for the third quarter ended September 30, 2022. Revenues for the quarter were $26.5 million. The company continued to advance its clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence.
Reported data updates from the Phase 1/2 STAAR study’s dose escalation phase for Fabry disease.
Dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003 for sickle cell disease.
Dosed the second patient in the Phase 1/2 STEADFAST study evaluating TX200 for Renal Transplant Rejection.
Announced, with Pfizer, the resumption of recruitment in the Phase 3 AFFINE trial for Hemophilia A.
Forward Guidance
Sangamo expects GAAP total operating expenses to be in the range of approximately $315 million to $325 million and non-GAAP total operating expenses to be in the range of approximately $280 million to $290 million for 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...